Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691.

Abstract:

:Recombinant interferon alpha-2b (IFN-alpha2) has direct and indirect antiproliferative effects in lymphoma, and may augment cytotoxicity when combined with chemotherapy. CALGB 8691 is a randomized study of daily oral cyclophosphamide (CPA) at 100 mg/m2 with or without IFN-alpha2 at 2 x 106 IU/m2 three times per week, followed by a second randomization between IFN-alpha2 maintenance (2 x 106 IU/m2 three times weekly) versus observation in treatment-naïve patients with follicular lymphoma (FL). Five hundred eighty-one patients were randomized to either CPA (n = 293) or CPA plus IFN-alpha2 (n = 288). One hundred five responding patients were randomized to observation and 99 to maintenance IFN-alpha2. With a median follow-up of 11.5 years, the median event-free and overall survival (OS) for CPA induction alone were 2.5 years (95% CI 2.2, 3.0) and 9 years (95% CI 7.7, 10.2), compared to 2.4 years (95% CI 2.1, 3.1) and 8.4 years (95% CI 7.5, 11.1) for the combination arm (p = NS). Patients with a partial response (PR) and randomized to observation had the worst outcome (event-free survival (EFS) 1.8 years versus 3.9 years; p = 0.002). Patients with a PR randomized to IFN-alpha2 had a similar EFS to compared to patients with complete response (CR), but this did not translate into a survival advantage. Myelosuppression was increased in IFN-alpha2-containing arms. Despite the small benefit in EFS in patients with PR randomized to IFN-alpha2 maintenance, we conclude that the addition of low dose IFN-alpha2 did not significantly improve the response rate, duration of response, event-free, or OS obtained with single-agent daily oral CPA in patients with previously untreated FL.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Smith SM,Johnson J,Cheson BD,Canellos G,Petroni G,Oken M,Duggan D,Hurd D,Gockerman JP,Parker B,Prchal J,Peterson BA,Cancer and Leukemia Group B.,Eastern Cooperative Oncology Group.

doi

10.1080/10428190903093807

subject

Has Abstract

pub_date

2009-10-01 00:00:00

pages

1606-17

issue

10

eissn

1042-8194

issn

1029-2403

pii

913275241

journal_volume

50

pub_type

杂志文章,多中心研究,随机对照试验
  • Detection of mutations in GATA1 gene using automated denaturing high-performance liquid chromatography and direct sequencing in children with Down syndrome.

    abstract::Denaturing high-performance liquid chromatography (dHPLC) was developed to screen DNA variations by separating heteroduplex and homoduplex DNA fragments by ion-pair reverse-phase liquid chromatography. In this study, we have evaluated the dHPLC screening method and direct sequencing for the detection of GATA1 mutation...

    journal_title:Leukemia & lymphoma

    pub_type: 信件

    doi:10.1080/10428190902829433

    authors: Amorim MR,Figueiredo AB,Splendore A,Magalhães IQ,Pombo-de-Oliveira MS,El-Jaick KB,D'andrea ML,Aquino J,Alencar DM,Brandalise SR,Burlemaqui L,Cardoso TC,Carvalho EG,Coser VM,Costa I,Dorea D,Drumond M,Lopes VG,Mendonça

    更新日期:2009-05-01 00:00:00

  • Long-term follow-up study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin's lymphoma.

    abstract::The present study has explored the possible value of sCA-125 as a prognostic factor in Hodgkin's lymphoma (HL). From August 1992 to June 2005 sCA-125 was measured at presentation and at the end of the treatments in 221 newly diagnosed adult patients with HL. In this study 90/221 (41%) patients showed a value greater t...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190601183710

    authors: Russo F,Lastoria S,Svanera G,Capobianco G,de Chiara A,Francia Rd,Squame E,de Martinis F,Pinto A

    更新日期:2007-04-01 00:00:00

  • The expression of anamorsin in diffuse large B cell lymphoma: possible prognostic biomarker for low IPI patients.

    abstract::Anamorsin is a cell-death-defying factor, which was originally isolated as a molecule that conferred resistance to apoptosis induced by growth factor starvation. In order to evaluate anamorsin expression levels in malignant lymphoma, we immunostained paraffin-embedded sections with anti-anamorsin monoclonal antibodies...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701713697

    authors: Shizusawa T,Shibayama H,Murata S,Saitoh Y,Sugimoto Y,Matsumura I,Ogawa H,Sugiyama H,Fukuhara S,Hino M,Kanamaru A,Yamauchi A,Aozasa K,Kanakura Y

    更新日期:2008-01-01 00:00:00

  • Case 36: a difficult diagnosis in a patient with fever and progressive multi-organ failure.

    abstract::A man in late middle age presented with fever, systemic symptoms, raised inflammatory markers and anaemia of chronic disease. Despite two months of investigation, the diagnosis of a haematological malignancy was made only at autopsy. ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701342703

    authors: Gabriel IH,Chong N,Rice A,Negus R,Bain BJ

    更新日期:2007-07-01 00:00:00

  • Emerging molecular predictive and prognostic factors in acute myeloid leukemia.

    abstract::Recurrent cytogenetic abnormalities have provided the backbone for prognosticating acute myeloid leukemia and predicting response to consolidative therapies for decades. However, more than 45% of acute myeloid leukemia patients have normal cytogenetics on both karyotype and fluorescence in situ hybridization at diagno...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1393669

    authors: McCurdy SR,Levis MJ

    更新日期:2018-09-01 00:00:00

  • Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.

    abstract::This phase-I/phase-II study evaluated panobinostat in combination with ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory classical Hodgkin lymphoma. During phase I, panobinostat was given daily on Monday/Wednesday/Friday starting one week prior to Cycle 1 (C1) of ICE and during two weeks of C1-2 of ICE...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/10428194.2017.1359741

    authors: Hu B,Younes A,Westin JR,Turturro F,Claret L,Feng L,Fowler N,Neelapu S,Romaguera J,Hagemeister FB,Rodriguez MA,Samaniego F,Fayad LE,Copeland AR,Nastoupil LJ,Nieto Y,Fanale MA,Oki Y

    更新日期:2018-04-01 00:00:00

  • Expression of HOX genes in acute leukemia cell lines with and without MLL translocations.

    abstract::In primary cells from acute leukemia patients, expression of the genes MEIS1, HOXA5, HOXA7 and HOXA9 has been reported to be correlated with the occurrence of MLL translocations. It was our aim to find out whether MLL mutant (MLLmu) and MLL wild-type (MLLwt) acute leukemia-derived cell lines might likewise be discrimi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001609942

    authors: Quentmeier H,Dirks WG,Macleod RA,Reinhardt J,Zaborski M,Drexler HG

    更新日期:2004-03-01 00:00:00

  • Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines.

    abstract::The relative scarcity of Hodgkin (H) and Reed-Sternberg (RS) cells within biopsies from cases with Hodgkin's disease (HD) is an impediment to the analysis of the nature and function of these cells. Continuous cell lines as uniform and permanently available sources of cells provide a valid alternative. Development of H...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199309148499

    authors: Drexler HG

    更新日期:1993-01-01 00:00:00

  • Plasma cell tumors in HIV-positive patients: report of a case and review of the literature.

    abstract::Plasma cell tumors show an increased incidence in HIV-positive patients. The cases reported in the literature suggest that plasma cell tumors occur in a younger age group than that encountered in the general population. Pathologically, many of these tumors show a plasmablastic morphology. Plasma cell tumors in HIV-pos...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190500054566

    authors: Salarieh A,Rao C,Gottesman SR,Alagha O,Todor R,Axiotis CA

    更新日期:2005-07-01 00:00:00

  • Techniques for detection of minimal residual disease.

    abstract::Analysis of leukemia-specific and leukemia-associated markers following standard or high-dose treatments is crucial in order to evaluate the efficacy of therapeutic strategies. During the last decade, several techniques have been proposed and used for detecting minimal residual disease (MRD). Each approach is characte...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509075308

    authors: Carlo-Stella C,Mangoni L,Dotti GP,Rizzoli V

    更新日期:1995-01-01 00:00:00

  • Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis.

    abstract::Isolated myeloid sarcoma (MS) is a rare extramedullary presentation of acute myeloid leukemia (AML). Little is known about MS outcomes due to its rarity. A population-based analysis of MS using the Survival, Epidemiology, and End Results (SEER) database was performed. We identified 345 patients, aged 15 or older, diag...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.963080

    authors: Movassaghian M,Brunner AM,Blonquist TM,Sadrzadeh H,Bhatia A,Perry AM,Attar EC,Amrein PC,Ballen KK,Neuberg DS,Fathi AT

    更新日期:2015-06-01 00:00:00

  • Frequent altered distribution of peripheral B-lymphocyte subsets in pediatric and adolescent patients with classical Hodgkin lymphoma.

    abstract::Peripheral lymphopenia is a well-known negative prognostic marker in classical Hodgkin lymphoma (cHL). We characterized the peripheral B-cell compartment in a prospective cohort of 83 pediatric cHL patients. We observed significantly low total B-cell counts (<100 cells/µl) in 31 of 83 patients (37%). More specifically...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1834090

    authors: Hamdi L,Creidy R,Boudjemaa S,Hendel-Chavez H,Hugues P,Taoufik Y,Leblanc T,Coulomb A,Krzysiek R,Landman-Parker J,Besson C

    更新日期:2020-10-23 00:00:00

  • Clinicopathological analysis of follicular lymphoma with a polyploid karyotype.

    abstract::The prognostic significance of specific cytogenetic abnormalities in follicular lymphoma (FL) is an area of ongoing research. A small percentage of FL are characterized by a polyploid karyotype. Several studies have analyzed ploidy level to determine its role as an independent prognostic factor in non-Hodgkins lymphom...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809092694

    authors: James GK,Horsman D,Connors JM,Klasa R,Wilson K,Argatoff L,Gascoyne RD

    更新日期:1998-01-01 00:00:00

  • Response to hyperfractionated accelerated radiotherapy in chemotherapy-refractory non-Hodgkin lymphoma.

    abstract::Patients with chemotherapy-refractory non-Hodgkin lymphoma (NHL) have a poor prognosis with a median overall survival (OS) of only 10 months. To investigate the role of radiotherapy (RT) in such patients, we conducted a retrospective review of 17 patients with biopsy-proven refractory NHL who received hyperfractionate...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1719096

    authors: Kim DW,Lee G,Lee H,Mahal AR,Lam MB,Ng AK

    更新日期:2020-06-01 00:00:00

  • Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States.

    abstract::The epidemiology of splenic marginal zone lymphoma (SMZL) in the United States has not been addressed. Eight years of data (2001-2008) from 17 registries of the Surveillance, Epidemiology and End Results (SEER) program were used for this study. Of the 116,411 cases of non-Hodgkin lymphoma (NHL) in the registries, 763 ...

    journal_title:Leukemia & lymphoma

    pub_type: 历史文章,杂志文章

    doi:10.3109/10428194.2012.743655

    authors: Liu L,Wang H,Chen Y,Rustveld L,Liu G,Du XL

    更新日期:2013-07-01 00:00:00

  • The role of FAS-mediated apoptosis in chronic myelogenous leukemia.

    abstract::Clinical observation and laboratory evidence suggest that immune mechanisms play an important role in the natural control of evolution of the Ph+ clone in chronic phase as well as during progression of chronic myelogenous leukemia (CML). The understanding of these mechanisms could facilitate development of innovative ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190009089429

    authors: Selleri C,Maciejewski JP

    更新日期:2000-04-01 00:00:00

  • Fas receptor (CD95)-mediated apoptosis in leukemic cells.

    abstract::Binding of Fas ligand (FasL) or an agonistic anti-Fas receptor (Fas/CD95) antibody induces apoptosis in Fas-bearing target cells. The involvement of Fas/FasL pathway has been investigated in human acute myelogenous leukemia (AML) cells. Fas/CD95 is expressed on a majority of AML cells, although the intensity of expres...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199709042492

    authors: Komada Y,Sakurai M

    更新日期:1997-03-01 00:00:00

  • The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.

    abstract::From July 1983 to January 1991 a total of 622 patients were randomized (585 eligible) to compare the effects of hydroxyurea, interferon alpha (IFN), and busulfan on the duration of chronic phase, and survival. Further goals included the determination of prognostic parameters. 598 CML patients were documented and 575 e...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.3109/10428199309047880

    authors: Hehlmann R,Heimpel H,Kolb HJ,Heinze B,Hochhaus A,Griesshammer M,Pralle H,Queisser WP,Essers U,Falge C

    更新日期:1993-01-01 00:00:00

  • The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma.

    abstract::Histological transformation of low-grade non-Hodgkin lymphoma (NHL) to diffuse large cell NHL is well recognized and is associated with a poor prognosis. We sought to determine the overall outcome and the factors that affect survival in patients with histological transformation of low-grade NHL. Between November 1979 ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600757894

    authors: Micallef IN,Remstein ED,Ansell SM,Colgan JP,Inwards DJ,Johnston PB,Lewis JT,Markovic SN,Porrata LF,White WL,Witzig TE,Ristow K,Habermann TM

    更新日期:2006-09-01 00:00:00

  • 2'-Deoxycoformycin for hepatosplenic gammadelta T-cell lymphoma.

    abstract::We describe a patient with unusually indolent hepatosplenic gammadelta T cell lymphoma characterised by severe lassitude and high fever. No significant responses were obtained to a range of chemotherapeutic and biological agents. 2'-deoxycoformycin (dCF), however, produced a dramatic and sustained clinical and histolo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109099342

    authors: Grigg AP

    更新日期:2001-08-01 00:00:00

  • Effects of parathyroid hormone-related protein and macrophage inflammatory protein-1α in Jurkat T-cells on tumor formation in vivo and expression of apoptosis regulatory genes in vitro.

    abstract::Parathyroid hormone-related protein (PTHrP) and macrophage inflammatory protein-1α (MIP-1α) have been implicated in the pathogenesis of adult T-cell leukemia/lymphoma, but their effects on T-cells have not been well studied. Here we analyzed the functions of PTHrP and MIP-1α on T-cell growth and death both in vitro an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.626883

    authors: Shu ST,Dirksen WP,Lanigan LG,Martin CK,Thudi NK,Werbeck JL,Fernandez SA,Hildreth BE 3rd,Rosol TJ

    更新日期:2012-04-01 00:00:00

  • Extranodal adult T-cell leukemia/lymphoma of the head and neck: a clinicopathological study of nine cases and a review of the literature.

    abstract::Extranodal adult T-cell leukemia/lymphoma (ATLL) of the head and neck is a rare disease. We studied the clinicopathological features of nine patients with ATLL involving extranodal head and neck sites and conducted a literature review. Six patients presented with extranodal mass of the head and neck, whereas three had...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190802702383

    authors: Miyagi T,Nagasaki A,Taira T,Shinhama A,Suzuki M,Ohshima K,Takasu N

    更新日期:2009-02-01 00:00:00

  • Defects in signal transduction pathways in chronic B lymphocytic leukemia cells.

    abstract::B chronic lymphocytic leukemia (B-CLL) and hairy cell leukemia (HCL) cells are refractory to many of the signals which activate normal B cells but are stimulated to proliferate by tumor necrosis factor (TNF). Cell signalling by TNF is mediated in part by the induction of the transcription factor families AP-1 and NF-k...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509064938

    authors: Jabbar SA,Hoffbrand AV,Wickremasinghe RG

    更新日期:1995-06-01 00:00:00

  • Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro.

    abstract::FB2 is a novel Abl/Src dual tyrosine kinase inhibitor which is designed to overcome imatinib resistance. Besides imatinib-sensitive cell lines (K562), FB2 significantly inhibited the growth of imatinib-resistant cell lines of different resistance mechanisms (K562/G5.0 and K562/G01), and decreased the expression of aut...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190802709438

    authors: Liu H,Li H,Feng Z,Tai J,Meng Y,Wang H,Xin H,Zhang S,Zuo M,Zhang Y,Chen X

    更新日期:2009-03-01 00:00:00

  • High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.

    abstract::The term high-risk multiple myeloma is aimed to identify a heterogeneous group of patients who are more likely to progress and die early of their disease. Therefore, recognition of these patients is crucial. With the increase in the number of treatment options, the outcome for high-risk patients has probably improved,...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2016.1233540

    authors: Muchtar E,Magen H,Gertz MA

    更新日期:2017-06-01 00:00:00

  • Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes databa

    abstract::We describe the patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for the initial staging of patients with newly diagnosed grade 1-2 follicular lymphoma (FL) and its potential impact on treatment. Data were obtained from the National Comprehensive Cancer Network Non-Hodgkin Lymphoma...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2013.770151

    authors: Abou-Nassar KE,Vanderplas A,Friedberg JW,Abel GA,Niland J,Rodriguez MA,Czuczman MS,Millenson M,Crosby A,Gordon LI,Zelenetz AD,Kaminski M,Lacasce AS

    更新日期:2013-10-01 00:00:00

  • Guillain-Barre-Strohl syndrome unraveled as paraneoplastic syndrome of B-cell acute lymphoblastic leukemia in a patient with preceding common variable immunodeficiency syndrome with Evans syndrome.

    abstract::A 26-year-old man with a history of common variable immunodeficiency and Evans syndrome (immunthrombocytopenia and immunhemolytic anemia) with sarcoid like lesions and lymph node enlargements in the previous history is described. The patient presented with symptoms resembling Guillain-Barre-Strohl as paraneoplastic sy...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000123474

    authors: Mailänder V,Gleisner B,Blau IW,Thiel E

    更新日期:2004-01-01 00:00:00

  • Transient abnormal myelopoiesis in Down's syndrome.

    abstract::Recent data have elucidated the pathogenesis of transient abnormal myelopoiesis (TAM) to a great extent. TAM is a monoclonal disorder which resolves spontaneously and the target cell in this disorder is a multipotent stem cell which is capable of differentiating into megakaryocytes. The pathogeneses of TAM/AMKL (acute...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199209051029

    authors: Kurahashi H,Hara J,Yumura-Yagi K,Tawa A,Kawa-Ha K

    更新日期:1992-12-01 00:00:00

  • CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.

    abstract::Few reports on the successful treatment of T-cell large granular lymphocyte (LGL) leukemia with the humanized anti-CD52 monoclonal antibody alemtuzumab are emerging in the literature. The expression of CD52 by LGLs has not been previously investigated. Using semi-quantitative 2- and 3-color flow cytometry, we document...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500052156

    authors: Osuji N,Del Giudice I,Matutes E,Morilla A,Owusu-Ankomah K,Morilla R,Dunlop A,Catovksy D

    更新日期:2005-05-01 00:00:00

  • Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma.

    abstract::The prednisone, etoposide, procarbazine and cyclophosphamide (PEP-C) oral combination chemotherapy regimen (prednisone 20 mg, cyclophosphamide 50 mg, etoposide 50 mg, and procarbazine 50 mg with an oral anti-emetic) was employed at our center to treat 22 patients with heavily pretreated, recurrent mantle cell lymphoma...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701837330

    authors: Coleman M,Martin P,Ruan J,Furman R,Niesvizky R,Elstrom R,George P,Leonard J,Kaufmann T

    更新日期:2008-03-01 00:00:00